Actinium Pharmaceuticals, Inc. SEC filings ATNM
Actinium Pharmaceuticals, Inc. has 511 filings in SEC EDGAR's recent list, going back to Feb 5, 2007. Its latest annual report, Form ARS, was filed on Oct 15, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 7, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 15, 2026 (officer or director change, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Oct 9, 2026 | — |
| S-8 | Employee stock plan registration | Mar 29, 2024 | — |
| S-3/A | Pre-effective amendment no. 1 to form s-3 | Feb 2, 2024 | — |
| S-3 | Shelf registration | Aug 11, 2023 | — |
| S-8 | Employee stock plan registration | Aug 19, 2022 | — |
| 424B3 | Prospectus | Jun 28, 2022 | — |
| S-3 | Shelf registration | Aug 7, 2020 | — |
| 424B5 | Prospectus supplement | Jun 18, 2020 | — |
| 424B5 | Prospectus supplement | Jun 16, 2020 | — |
| 424B5 | Prospectus supplement | Apr 22, 2020 | — |
| 424B5 | Prospectus supplement | Apr 21, 2020 | — |
| S-8 | Employee stock plan registration | May 10, 2019 | — |
| 424B5 | Prospectus supplement | Apr 18, 2019 | — |
| 424B5 | Prospectus supplement | Apr 17, 2019 | — |
| 424B5 | Prospectus supplement | Dec 28, 2018 | — |
| 424B5 | Prospectus supplement | Oct 18, 2018 | — |
| S-8 | Employee stock plan registration | Mar 16, 2018 | — |
| 424B5 | Prospectus supplement | Feb 26, 2018 | — |
| 424B5 | Prospectus supplement | Feb 15, 2018 | — |
| 424B5 | Prospectus supplement | Feb 1, 2018 | — |
| 424B3 | Prospectus | Oct 24, 2017 | — |
| 424B3 | Prospectus | Oct 24, 2017 | — |
| S-3/A | Amendment no. 1 to form s-3 | Oct 3, 2017 | — |
| 424B5 | Prospectus supplement | Jul 31, 2017 | — |
| 424B5 | Prospectus supplement | Jul 27, 2017 | — |
| 424B5 | Prospectus supplement | Jul 3, 2017 | — |
| S-3 | Shelf registration | Mar 16, 2017 | — |
| S-8 | Employee stock plan registration | Mar 16, 2017 | — |
| 424B5 | Prospectus supplement | Sep 29, 2016 | — |
| 424B5 | Prospectus supplement | Sep 28, 2016 | — |
| 424B5 | Prospectus supplement | Jun 5, 2015 | — |
| 424B5 | Prospectus supplement | Feb 6, 2015 | — |
| 424B5 | Prospectus supplement | Feb 5, 2015 | — |
| S-8 | Employee stock plan registration | Jul 7, 2014 | — |
| 424B5 | Prospectus supplement | Jun 25, 2014 | — |
| 424B5 | Prospectus supplement | Jun 24, 2014 | — |
| 424B3 | Prospectus | Apr 18, 2014 | — |
| 424B3 | Prospectus | Apr 18, 2014 | — |
| S-3/A | Registration statement | Apr 10, 2014 | — |
| S-3 | Shelf registration | Mar 24, 2014 | — |
| 424B3 | Prospectus | Mar 19, 2014 | — |
| 424B3 | Prospectus | Mar 19, 2014 | — |
| 424B3 | Prospectus | Feb 20, 2014 | — |
| S-1/A | Amended registration statement | Feb 12, 2014 | — |
| S-1 | Registration statement | Jan 31, 2014 | — |
| 424B3 | Prospectus | Nov 19, 2013 | — |
| 424B3 | Prospectus | Nov 13, 2013 | — |
| S-1/A | Amended registration statement | Oct 28, 2013 | — |
| S-1 | Registration statement | Sep 30, 2013 | — |
| S-1/A | Amended registration statement | Aug 22, 2013 | — |
| S-1 | Registration statement | Mar 15, 2013 | — |
Showing 51 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ATNM (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1388320
- Former names
- Cactus Ventures, Inc. (until Mar 29, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.